$HUTCHMED(00013)$ has been pre

$HUTCHMED(00013)$ has been pretty beaten down lately, mostly due to some negative buzz around major shareholders. But honestly, this might just be a buying opportunity.

Their core product, Fruquintinib, pulled in $290 million in overseas sales last year, with $110 million going straight into Hutchmed’s pocket, that’s top-tier among Chinese drugs going global, just behind Brukinsa and Xalkori.

Plus, they’ve got $800 million in cash sitting around, and another $600 million coming in from selling their TCM business, that’s $1.4 billion total. In the cutthroat world of innovative pharma, that kind of war chest means survival and staying power. At current prices, this could be the calm before the bounce.

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":427918733484248,"tweetId":"427918733484248","gmtCreate":1745477567565,"gmtModify":1745480446200,"author":{"id":9000000000000682,"idStr":"9000000000000682","authorId":9000000000000682,"authorIdStr":"9000000000000682","name":"BertScott","avatar":"https://static.tigerbbs.com/7abe9a5ceed1650d274c1ec776021cd1","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/91997961e23cda6d7cbc81be00f6e8c9","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/91997961e23cda6d7cbc81be00f6e8c9","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> has been pretty beaten down lately, mostly due to some negative buzz around major shareholders. But honestly, this might just be a buying opportunity. Their core product, Fruquintinib, pulled in $290 million in overseas sales last year, with $110 million going straight into Hutchmed’s pocket, that’s top-tier among Chinese drugs going global, just behind Brukinsa and Xalkori. Plus, they’ve got $800 million in cash sitting around, and another $600 million coming in from selling their TCM business, that’s $1.4 billion total. In the cutthroat world of innovative pharma, that kind of war chest means survival and staying power. At current prices, this could be the calm before the bounce.<img src=\"https://community-static.tradeup.com/news/91997961e23cda6d7cbc81be00f6e8c9\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> has been pretty beaten down lately, mostly due to some negative buzz around major shareholders. But honestly, this might just be a buying opportunity. Their core product, Fruquintinib, pulled in $290 million in overseas sales last year, with $110 million going straight into Hutchmed’s pocket, that’s top-tier among Chinese drugs going global, just behind Brukinsa and Xalkori. Plus, they’ve got $800 million in cash sitting around, and another $600 million coming in from selling their TCM business, that’s $1.4 billion total. In the cutthroat world of innovative pharma, that kind of war chest means survival and staying power. At current prices, this could be the calm before the bounce.<img src=\"https://community-static.tradeup.com/news/91997961e23cda6d7cbc81be00f6e8c9\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$HUTCHMED(00013)$ has been pretty beaten down lately, mostly due to some negative buzz around major shareholders. But honestly, this might just be a buying opportunity. Their core product, Fruquintinib, pulled in $290 million in overseas sales last year, with $110 million going straight into Hutchmed’s pocket, that’s top-tier among Chinese drugs going global, just behind Brukinsa and Xalkori. Plus, they’ve got $800 million in cash sitting around, and another $600 million coming in from selling their TCM business, that’s $1.4 billion total. In the cutthroat world of innovative pharma, that kind of war chest means survival and staying power. At current prices, this could be the calm before the bounce.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/427918733484248","repostId":0,"isVote":1,"tweetType":1,"viewCount":2380,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["00013"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":599,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/427918733484248"}